Company intelligence / Profile preview

MicroGeneSys

Meriden, Connecticut, United States
Ownership
Private
Development stage
Other
01

Overview

MicroGeneSys was a pioneering biopharmaceutical company known for developing VaxSyn, the first HIV/AIDS vaccine candidate to enter human clinical trials in the United States in 1987. The company was a leader in using the Baculovirus Expression Vector System (BEVS) to produce recombinant proteins. Despite early promise and significant political visibility, the company's vaccine candidates failed to show sufficient efficacy in Phase 2 trials, and the company eventually ceased operations in the mid-1990s following financial and legal difficulties.

Therapeutic areas
Infectious Diseases
Modalities
VaccineRecombinant protein
Industry
Biotech
02

Drug pipeline

2 assets

HIV-1 gp160

1

1 more asset in the full pipeline.

Request access →
03

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)Walter Reed Army Institute of Research

Beyond the preview

Go deeper on MicroGeneSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroGeneSys.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call